Skip to Content
Merck
CN

SML3060

Panobinostat

≥98% (HPLC), Pan-histone deacetylase inhibitor, powder

Synonym(s):

(2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide, LBH 589, LBH-589, LBH589, N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, NVP-LBH589

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C21H23N3O2
CAS Number:
404950-80-7
Molecular Weight:
349.43
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
MFCD09833242

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Panobinostat, ≥98% (HPLC)

InChI

1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+

SMILES string

CC1=C(CCNCC2=CC=C(/C=C/C(NO)=O)C=C2)C3=CC=CC=C3N1

InChI key

FPOHNWQLNRZRFC-ZHACJKMWSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Orally active, potent, cinnamoyl hydroxamate-type pan-histone deacetylase inhibitor with anti-cancer efficacy in vitro and in vivo.
Panobinostat (LBH589) is an orally active, potent, cinnamoyl hydroxamate-type pan-histone deacetylase inhibitor (class I HDAC1/2/3/8 IC50 = 2.5/13.2/2.1/277 nM; IIA HDAC4/5/7/9 IC50 = 203/7.8/531/5.7 nM; IIB HDAC6/10 IC50 = 10.5/2.3 nM, IV HDAC11 IC50 = 2.7 nM) with anti-cancer efficacy in vitro and in vivo.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Inhalation

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000450073
0000450074
0000450074
0000450073
0000366703

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kenji Fujimoto et al.
Neuro-oncology advances, 2(1), vdaa084-vdaa084 (2020-08-15)
Polyglutamylation is a reversible protein modification that commonly occurs in tumor cells. Methotrexate (MTX) in tumor cells is polyglutamylated and strongly binds to dihydrofolate reductase (DHFR) without competitive inhibition by leucovorin. Therefore, tumor cells with high polyglutamylation levels are supposed
Chie Ishikawa et al.
European journal of haematology, 105(6), 763-772 (2020-08-12)
New effective therapeutic strategies for human T-cell leukemia virus type 1 (HTLV-1)-driven adult T-cell leukemia (ATL) are required because of resistance to chemotherapeutic agents. Here, we aimed to determine the therapeutic efficacy of a dual phosphoinositide 3 kinase (PI3K)/histone deacetylase
Peter Atadja
Cancer letters, 280(2), 233-241 (2009-04-07)
The histone deacetylase (HDAC) inhibitors are emerging as a highly useful class of anticancer agents that inhibit the enzyme HDAC involved in the deacetylation of histone and non-histone cellular proteins. The HDAC inhibitor, panobinostat (LBH589, Novartis Pharmaceuticals), achieves potent inhibition
Shan Su et al.
Frontiers in microbiology, 11, 1584-1584 (2020-08-09)
Invasive fungal infections are an emerging problem worldwide, which bring huge health challenges. Candida albicans, the most common opportunistic fungal pathogen, can cause bloodstream infections with high mortality in susceptible hosts. At present, available antifungal agents used in clinical practice
Yang Zhang et al.
Frontiers in cell and developmental biology, 8, 652-652 (2020-08-15)
We investigated the therapeutic potential of targeting integrin/FAK-dependent signaling, an adhesion receptor-mediated pathway that has been increasingly linked to non-small cell lung cancer (NSCLC) malignancy. Our analysis of the TCGA cohort showed that a subset of pro-tumorigenic integrins, including α1β1
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service